Sequana Medical announces H1 2022 results and provides business update
REGULATED INFORMATION – INSIDE INFORMATION
8 September 2022, 07:00 CET
- alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022
- DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study in H1 2023
- Total liquidity position of €23.8 million and cash runway into Q3 2023
Conference call with live webcast presentation today at 03:00 pm CET / 09:00 am ET
Ghent, Belgium – 8 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.
Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We have made important progress with both our liver disease and heart failure programs during this reporting period. Our POSEIDON study for the alfapump in patients with liver disease continues to report strong interim results, including 70% 12 month survival for the Roll-In cohort, and we look forward to reporting primary endpoint data for the Pivotal cohort by year end. We are excited to see the continued strong clinical evidence of a disease-modifying profile for our DSR program for diuretic-resistant heart failure patients. In addition to no congestion-related re-hospitalizations during their study follow-up, which is remarkable given that typically one in four of these patients is re-admitted within a month of discharge, the 75% reduction in predicted 12 month mortality is highly promising for this patient group in need of improved clinical options. The evidence from our proof-of-concept studies show the long-term clinical benefits delivered by Short Term DSR therapy and we look forward to further demonstrating DSR’s potential in MOJAVE, our upcoming US phase 1b/2a multi-centred, randomized, controlled study with DSR 2.0, our second-generation DSR product.
“Finally, the two highly experienced US medtech executives that we have added to our Board bring important expertise as we prepare for US commercialization of the alfapump, and we are well capitalised into Q3 2023 having successfully raised additional finance.”